Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
9-ING-41 in Pediatric Patients With Refractory Malignancies.

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

pleural effusion
mibg
stem cell infusion
iobenguane
monoclonal antibodies
  • 0 views
  • 14 May, 2022
  • 8 locations
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease. Despite this terrible and frustrating outcome, continued treatment of this population remains fundamental to improving cure rates. Studying this relapsed population will help unearth clues to why conventional therapy …

gemcitabine
combinations
combined modality therapy
recurrent brain tumors
medulloblastoma
  • 231 views
  • 19 Apr, 2022
  • 1 location
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.

pain relief
gabapentin
analgesics
pregabalin
NSAID
  • 12 views
  • 24 Jan, 2021
Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas (TransMenAtyp)

Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II). Retrospective observational study, on a cohort of 85 atypical

  • 0 views
  • 13 Mar, 2022
  • 1 location
Predictive Factors of Visual Recovery After Paraoptic Tumors Removal (PRONOPTIC)

Paraoptic tumors - including mostly sellar meningiomas, pituitary gland adenomas and craniopharyngiomas - classically affect the visual function. Some preoperative factors, determined on

  • 7 views
  • 24 Mar, 2022
  • 1 location
Oncological Care for Patients With Meningioma (ATYPICMENING)

Meningiomas with malignant components include grade II meningiomas (GIIM, the most common ones) and grade III meningiomas (GIIIM). They represent 5-35% of all meningiomas. Histological diagnosis

  • 5 views
  • 03 May, 2022
  • 1 location
Androcur (Cyproterone Acetate) and Meningioma Development: a Genotype-environment Association Study

The primary objective of the study is to create a biobank of oral smears permitting to identify the genetic locus/loci associated with an increased risk to develop meningiomas after cyproterone

cyproterone acetate
x-rays
Accepts healthy volunteers
  • 0 views
  • 10 Oct, 2021
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON) (SOLOMON)

The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not …

brain tumor
  • 0 views
  • 08 Mar, 2022
  • 1 location
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of …

karnofsky performance status
proton therapy
  • 0 views
  • 04 May, 2022
  • 3 locations
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.

  • 0 views
  • 26 May, 2022
  • 16 locations